MDNA 109

Drug Profile

MDNA 109

Alternative Names: MDNA109

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Stanford University
  • Developer Medicenna Therapeutics; Stanford University
  • Class Antineoplastics; Interleukins; Recombinant proteins; Small molecules
  • Mechanism of Action Immunostimulants; Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological disorders; Immunological disorders

Most Recent Events

  • 15 Dec 2016 Preclinical trials in Haematological disorders in USA (unspecified route)
  • 15 Dec 2016 Preclinical trials in Immunological disorders in USA (unspecified route)
  • 15 Dec 2016 Medicenna Therapeutics has patent protection for MDNA 109 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top